Weihansi Bio (韦翰斯生物) is a high-tech gene testing service platform that concentrates on genetic testing applications for hereditary diseases. The company aims to become a domestic leader in the genetic disease testing field. It develops products and services around genetic diagnostics and is pursuing registration filings. Weihansi recently completed a B round financing of nearly ¥100 million. Proceeds will be used to strengthen its product lineup in genetic disease testing and the tertiary prevention of birth defects. The company also plans to expand its nationwide LDT laboratory footprint. 韦翰斯生物 develops genetic testing technologies and platforms centered on single-gene disease detection and reproductive health. The company has built multiple detection platforms (first- and second-generation sequencing, Bionano for structural variants, qPCR) and covers over 10 single-gene disease panels. It provides end-to-end solutions across preconception, prenatal and postnatal stages, and offers services including bioinformatics analysis and genetic counseling. 韦翰斯生物 has established commercial and research collaborations with hundreds of top medical institutions and claims leadership in noninvasive prenatal single-gene diagnosis (NIPD-MG). The company holds 31 patents, 33 software copyrights, 43 trademarks and 28 Class II/III medical device registrations. Its business has grown rapidly, averaging 2–3x annual growth, and it plans to continue expanding product lines and industrial-chain布局.

Total raised

$30M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2023